INS and obesity disorder: Taken together, our study using HFD-induced obesity animal model shows that MSDC-0602K, as a novel insulin sensitizer, has reduced detrimental effects on bone parameters and BM-MSC phenotype by activation of glutamine metabolism as compared to the first generation of TZDs, i.e. pioglitazone.